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Prevention of Viral Myocarditis With Recombinant Human Leukocyte
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Effects of recombinant human leukocyte interferon Q'
AID on experimental myocarditis due to encephalomy-
ecarditls virus were investigated. Plaque reduction as-
says revealed that 50% of plaque formation in vitro in
human amnion (FL) cells was inhibited by interferon Q'
AID (9.7 Vlml) when it was administered 24 hours before
infection with the encephalomyocarditis virus. Four week
old male DBAl2 mice were inoculated intraperitoneally
with 10 plaque-forming units (pfu) of encephalomy-
ocarditis virus. Interferon Q' AID was administered sub-
cutaneously (102 U/g body weight per day in Group 1,
103 Ulgper day in Group 2 and 104 U/g per day in Group
3) starting 1 day before infection. It was also adminis-
tered starting the same day in Group 4 and 1 day after
virus inoculation in Group 5 (104 U/g per day in both
groups). Control mice were injected with saline solution.
Each group consisted of 10 mice; they were killed on
day 4 for evaluation.
Interferon was discovered in 1957 by Isaacs and Lindemann
(I) and has been found to comprise a family of proteins that
share significant antiviral properties . Three major types of
interferon are known to exist. These include alpha, beta and
gamma interferons. Alpha interferon is generally produced
when leukocytes are exposed to viruses. Recombinant DNA
technology has shown that as many as 12 or more different
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Myocardial virus titers were significantly lower in
Group 3 (8.2 ± 25.2 x 102 pfulmg, p < 0.05) and Group
4 (3.0 ± 5.5 x 103 pfu/mg, p < ~.05) than in control
mice (5.6 ± 4.1 x 104 pfu/mg). Histologic examination
showed extensive myocardial necrosis and cellular infil-
tration in all control mice, but no myocardial necrosis
or cellular infiltration in Group 3 and lesssevere necrosis
and infiltration in Group 4. There were no significant
differences in myocardial virus titers or histologic changes
between control mice and Group I, 2 or 5.
Thus, interferon Q' AID, when administered starting
before or simultaneously with virus inoculation, effec-
tively inhibited myocardial virus replication and reduced
the inflammatory response and myocardial damage in
an experimental model of viral myocarditis.
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human alpha interferon genes and polypeptides exist in white
blood cells (2).
Natural human interferon preparations do not show sig-
nificant activity in mouse cells . However, a recombinant
human leukocyte interferon subtype aD and hybrid inter -
feron a AID were shown to have relatively high antiviral
activity in murine cell cultures and in vivo (3). In our study
we investigated the effect of recomb inant human leukocyte
interferon a AID on experimental viral myocarditis, using
a recently developed animal model (4, 5).
Methods
Virus. The M variant of encephalomyocarditis virus was
used . Virus stock was prepared as previously described (4)
and stored at - 70°C until diluted for use.
Viral titers were determined by plaque formation on hu-
man amnion (FL) cell monolayers. Cells were suspended
at a concentration of 1 x 10 6 in Eagle's minimal essential
medium with 15% fetal calf serum plus 100 ILg/ml of pen-
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Table 1. Effect of Interferon a AID on Encephalomyocarditis Virus Replication in the Heart:
Treatment Started I Day Before Virus Inoculation
Daily Dose No. of
Myocardial Virus Titer (pfu/mg)
Group (V lg) Mice Mean ± SD Range
Control None 10 5.6 ± 4.1 x 10· 4.5 x 1 0~- 1.3 x :::J NS] NS]I 102 10 7. 1 ± 6.8 x 10· 2.0 x 1 0~- 1.8 x
2 103 10 6.2 ± 7.2 x 10· 1.2 x 10 '- 2.3 x lOS *
3 10· 10 K.2 :!: 25.2 x IO~ 0-8.0 X 103
*p < 0.05.
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icillin and streptomycin in six-well plastic plates and were
allowed to grow for 4 days at 37°C in 5% carbon dioxide.
Volumes (0.1 ml) of decim al dilutions of virus suspen-
sions were adsorbed to FL cell monolayers for 60 minutes
at 37°C in 5% carbon dioxide . After adsorption, the cell s
were overlaid with 3 ml of medium containing 4% fetal calf
serum and 1% methylcellulose . After 2 days of incubation
at 37°C in a humid ified atmosphere conta ining 5% carbon
dioxide , cells were fixed with acetic acid and methanol (at
a ratio of 1:3) and stained with crystal violet (I %), and
plaque s were counted with an inverted microscope .
In vitro assays of interferon. Recombin ant human leu-
kocyte interferon a AID was supplied by Hoffmann-La-
Roche , Inc. Antiviral activit y of the drug in vitro was as-
sayed by a plaque reduction method . Confluent monolayers
of FL cells in six-well plastic plates were treated with me-
dium containing variou s concentrations of interferon a AID
(0, 1, 10 or 100 U/ml). Twenty-four hours later, cells were
washed three times with phosphate-buffered saline solution
and were inoculated with 100 plaque-forming units (pfu) of
enceph alomyocarditis virus. After adsorption, the cells were
overlaid as described earlier.
After 2 days of incubation at 3rC, cells were fixed with
acetic acid methanol, stained with crystal violet and plaques
were counted. Percent plaque formation was expressed as
percent of plaques of untreated cont rols. The drug concen -
tration required to reduce the number of plaque s by 50%
from the number in control wells (the median inhibitory
dose , ID50) was calculated from the graph relating plaque
number and drug concentrations on a semilog plot (linear
regression) (6).
Treatment of cells with increasing concentrations of in-
terf eron a AID resulted in progressive reduction of plaqu e
fo rmation. The mean percent plaque formation was 110.8 %
at an interferon a AID concentration of I U/ml, 34 .6% at
10 U/ml and 3.7% at 100 U/ml (each n = 5). Thus a
concentration of 10 U/ml of the drug was effective in re-
ducing the number of plaques produced by the virus, and
plaque formation was compl etely inhibited at 100 U/m!.
Linear regress ion analysis showed good negative correlation
of y = 9 1.9 - 48.5 10g lOx , r = - 0 .938, P < 0 .001 ,
between plaque -forming units and the logarithm of inter-
feron concentration. ID50 was 7.2 Uzrnl .
Virus inoculation and treatment of mice. Four week
old male DBAl2 mice (Jackson Laboratory) were inoculated
intraperitoneall y with 0 .1 ml of encephalomyocarditis virus
diluted in Eagle 's minimal essential medium to a concen -
tration of 100 pfu/m!. Interferon a AID was administered
subcutaneously at a dose of 102 (Group I), 103 (Group 2)
or 104 (Group 3) U/g body weight once daily, beginn ing I
day before virus inoculation . Interferon a AID, 104 U/g per
day , was also given starting the same day (Group 4) and 1
day after (Group 5) virus inoculation. Control mice were
injected with saline solution. Each group consisted of 10
mice. Mice were killed on day 4.
Mice used in our study were maintained in accordance
with guidelines of the Committee on Animals of the Harvard
Medical School and those prepared by the Committee on
Care and Use of Laboratory Animals of the Institute of
Laboratory Animal Resource s, National Research Counc il,
Department of Health , Education and Welfare , Department
of Health and Human Services, National Institutes of Health
publ ication 78-23, revised 1978.
Virus titers of tis sues. For infectivity assays. tissues
were removed aseptically, weighed and homogenized in 2
ml of Eagle ' s minim al esse ntial medium. After centrifu-
Table 2. Effect of Interferon a AID on Replication of Encephalomyocarditis Virus in the Heart:
Treatment With 104 Uzg per Day Started the Same Day or I Day After Virus Inoculation
Treatment No. of
Myocardial Virus Titer (pfu/mg)
Group Started Mice Mean ± SD Range
Control None 10 5.6 ± 4.1 x 10· 4.5 x 1O~- 1.3 x
10
5
] *]4 Day 0 10 3.0 ± 5.5 x 103 1.3-1. 8 x 10· NS
5 Day + I 10 6.0 ± 6.3 x 10· IA x 103-1.6 x 105 ] *
*p < 0.05 .
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Table 3. Effect of Interferon a AID on Myocardial Histopathology: Treatment Started I Day Before Virus Inoculation
Dose No. of
Histologic Grade
Group (Dig) Mice 0 1+ 2+ 3+ 4+ P Value*
Necrosis
Control 0 10 0 4 3 2 I
I 102 10 0 4 3 3 0 NS
2 103 10 6 2 I I 0 NS
3 104 10 10 0 0 0 0 <0.01
Infiltration
Control 0 10 0 4 2 3 I
I 102 10 0 4 3 3 0 NS
2 103 10 6 2 I I 0 NS
3 104 10 10 0 0 0 0 <0.01
Calcification
Control 0 10 0 5 2 2 I
I 102 10 0 5 2 3 0 NS
2 103 10 5 3 I I 0 NS
3 104 10 5 5 0 0 0 <0.05
*Kruskal-Wallis test versus control.
gation at 1,500g for 15 minutes at 4°C, supernatants were
inoculated into FL cell monolayers, and plaque assays were
performed. Virus titers in the brain were investigated in
Group 3 and control mice.
Histopathology. The hearts were fixed in 10% formalin
solution, embedded in paraffin and stained with hematox-
ylin-eosin. Myocardial cell necrosis, cellular infiltration and
calcification were scored by observers who were unaware
of other data on a scale of I + to 4 + in terms of severity
as previously described (7). A 1+ score described a limited
focal distribution of myocardial lesions. A 4 + score indi-
cated the presence of multiple lesions over the entire heart,
whereas scores of 2+ and 3+ were used to describe in-
termediate lesion severity.
Statistics. The Kruskal-Wallis test was used to evaluate
the difference between histologic gradings. Virus titers of
the heart were examined by an analysis of variance followed
by the Neuman-Keuls test for multiple sample comparison
(8).
Results
Mortality. None of the mice died before day 4. One
control mouse, two mice in Group I, one in Group 2 and
two in Group 5 died. No mice in Group 3 or4 died. Mortality
was not an end point of our study.
Myocardial virus titer (Tables 1 and 2). The myo-
cardial virus titer of the control group was 5.6 ± 4.1 X
104 pfu/mg (mean ± SD). Titers of treated groups were
7.1 ± 6.8 x 104 pfu/mg in Group 1, 6.2 ± 7.2 x 104
pfu/mg in Group 2, 8.2 ± 25.2 x 102 pfu/mg in Group
3, 3.0 ± 5.5 x 103 pfu/mg in Group 4 and 6.0 ± 6.3 x
Table4. Effect of Interferon a AID on Myocardial Histopathology: Treatment With 10" Dig per Day Started at the Same Day or
I Day After Virus Inoculation
Interferon (104 Dig) No. Histologic Grade
Group Started on Mice 0 1+ 2+ 3+ 4+ p* Value
Necrosis
Control Virus alone 10 0 4 3 2 I
4 Day 0 10 6 4 0 0 0 <0.01
5 Day +1 10 2 I 4 3 0 NS
Infiltration
Control Virus alone 10 0 4 2 3 I
4 Day 0 10 6 4 0 0 0 <0.01
5 Day +1 10 2 2 5 I 0 NS
Calcification
Control Virus alone 10 0 5 2 2 I
4 Day 0 10 7 3 0 0 0 <0.01
5 Day +1 10 2 4 4 0 0 NS
*Kruskal-Wallis Test versus control.
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104 pfulmg in Group 5. Myocardial virus titers were sig-
nificantly lower in Groups 3 and 4 compared with control
mice (p < 0.05).
Virus titers in the brain. Virus titer in the brain in
Group 3 was 4.5 ± 10.3 x 102 pfu/mg (range 0.\ to 3.3
x \03) and was significantly lowerthan that in control mice
(1.8 ± 1.4 x 103 pfu/mg, range 3.4 X 102 to 4.5 X 103 ,
P < 0.05).
Histologic findings (Tables 3 and 4, Fig. 1). Cellular
infiltration and myocardial necrosis were found in all un-
treated hearts but were absent in all hearts of mice in Group
3 and in 6 of 10 hearts in Group 4. Cellular infiltration and
myocardial necrosis were significantly less severe in Groups
3 and 4 than in other groups (p < O.a1).
Figure I. Histologic findings in hearts of mice inoculated with
encephalomyocarditis virus. A, Four days after virus inoculation.
marked inflammatory cell infiltration and extensive myocardial
necrosis are seen in an untreated mouse. B, On the other hand.
neither infiltration nor necrosis is seen in the heart of a mouse in
whichtreatment with 10" Uzg of interferon was started I day before
infection (Group 3). (Hematoxylin-eosin stain; original magnifi-
cation x 400, reduced by 27%).
Myocardial calcification was found in the hearts of all
untreated mice. in the hearts of half of the mice in Groups
2 and 3 and in 3 of 10 mice in Group 4. Myocardial cal-
cification was less severe in Groups 3 and 4 (p < 0.05).
When treatment with interferon a: ND (104 U'g per day.
Group 3) was started before or simultaneously with virus
inoculation, the inflammatory response and myocardial
damage were effectively reduced. Representative photo-
graphsof the heartsof treatedand untreated mice are shown
in Figure I.
Discussion
Interferon treatment for viral diseases. Recombinant
human leukocyte interferon is currently being tested in pa-
tients with cancer and viral diseases to assess its toxicity
andtherapeutic efficacy. Reported sideeffects includefever.
chills, fatigue, anorexia. myalgias, nausea, vomiting, head-
aches, dose-dependent reversible leukopeniaand elevations
of hepatic transaminase (9-11) . A placebo-controlled, dou-
ble-blind randomized study (12) showed that treatment with
low dose leukocyte alpha interferon markedly reduced
symptomatic cytomegalovirus infection in kidney transplant
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recipients. The use of recombinant alpha interferon for treat-
ment of hairy cell leukemia in humans has received approval
from the U.S. Food and Drug Administration. The side
effects have usually been dose-related and in many cases
may be managed successfully by the use of antipyretic agents
such as acetaminophen or by reducing the dose of interferon.
Studies are still underway to evaluate the role of interferon
in the treatment of several human viral diseases. For short-
term use in acute illness such as myocarditis, interferon
should be associated with minimal side effects.
Because interferon has multiple immunologic effects, it
may contribute to the body's defense against various mi-
crobial assaults. However, it appears likely that interferon
plays a significant role in the control of viral infections.
This assumption has been supported by a number of studies
that have suggested that neutralization of interferon using
specific antisera enhances the severity of viral infection.
Thus, Gresser et al. (13) demonstrated a role of interferon
in the pathogenesis of encephalomyocarditis virus infection
by treating mice with anti-mouse interferon globulin. In
mice treated with anti-mouse interferon globulin, the virus
was present in high titer in visceral organs and mice died
more frequently and earlier than did untreated mice. Goed-
del et al. (14) showed protective effects of recombinant
interferon-oA against the lethal infection of squirrel mon-
keys with encephalomyocarditis virus.
Subtypes of interferon. Week et al. (3) investigated
recombinant human leukocyte interferon subtype aA, aB,
aD and two hybrid interferons a AID and a DIA for in vivo
and in vitro activity. A single intraperitoneal injection of
104 U of interferon-aD or a AID 3 hours before infection
caused significant protection against lethal encephalomy-
ocarditis virus infection of CD-I mice. Treatment with in-
terferon-aA or a DIA did not cause significant protection
against encephalomyocarditis virus infection. Repeated
treatments with 102 , 103 or 104 U of interferon a AID caused
greater protection than did single treatments at the same
dose given 3 hours before infection. However, single or
multiple treatments at or after 24 hours postinfection did
not cause significant protection against encephalornyocar-
ditis virus infection with any of the interferon preparations.
Also, Giron and collaborators (IS) found that the production
of diabetes by the D strain of the encephalomyocarditis virus
was blocked by interferon-S, as well as by a variety of
interferon inducers in SWR/J mice. Effects of interferon-a
AID on the heart were not studied by these investigators.
However, interferon-,Bhas been shown to inhibit replication
of coxsackie virus B3 in cultured human heart cells (16).
Viral myocarditis due to encephalomyocarditis virus.
This virus is a picornavirus biologically similar to coxsackie
virus. It is periodically isolated in diagnostic and epide-
miologic investigations as the etiologic agent of disease in
domestic swine (17), captive wild animals or nonhuman
primates (18). Epizootic outbreaks of virus infection with
this virus have been reported in swine, manifesting as severe
and fatal myocarditis (19).
In our study, in an animal model of viral myocarditis,
we demonstrated that human leukocyte interferon a AID
given I day before or simultaneously with inoculation with
encephalomyocarditis virus inhibited multiplication of virus
in the heart and protected mice from developing myocar-
ditis. Prevention was dependent on dosage and on the time
of initiation of treatment. When treatment was started before
or simultaneously with virus inoculation, interferon a AID
in a dose of 104 U/g per day effectively reduced the inflam-
matory response and myocardial damage. Myocardial cal-
cification was less severe but was still seen in these groups.
Because early calcification follows myocardial necrosis in
this animal model (5,7), the focal calcification seen in these
groups may be the sequel of less severe myocardial necrosis.
Current therapy for viral myocarditis is symptomatic and
supportive, and specific treatment is not available. Recently,
we demonstrated in an animal model that a broad-spectrum
antiviral agent, ribavirin, protected mice from development
of encephalomyocarditis virus myocarditis (7). Mice treated
with ribavirin survived longer than did control mice. Ri-
bavirin inhibited encephalomyocarditis virus replication in
the heart, and this inhibitory effect correlated well with the
decrease in severity of myocardial damage and inflammatory
cellular infiltration. However, because of failure of ribavirin
to rapidly penetrate the blood-brain barrier, it did not inhibit
viral replication in the brain, even in mice treated with high
doses. In the present study, 104 U/g of interferon a AID
started 1 day before infection significantly reduced viral
replication in the brain.
Therapeutic implications. Interferon is a broadly active
antiviral agent and therefore should be of great advantage
in treating diseases of multiple etiology, such as viral res-
piratory or viral gastrointestinal illnesses, as well as viral
myocarditis. At first sight, the demonstrated beneficial ef-
fects of treatment with recombinant interferon-a AID before
and at the time of virus inoculation may appear to be of
little clinical value. However, clinical relevance may lie in
the protection of individuals infected in the laboratory or
exposed to epidemic outbreaks, such as those that occur
among infants, in hospital nurseries (20). We believe that
our results justify further study of the effects of interferon
a AID against other cardiotropic virus infections used with
or without other therapeutic agents.
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